Suppr超能文献

《难治性哮喘患者:一种系统的处理方法》。

The Difficult-to-Control Asthmatic: A Systematic Approach.

机构信息

Division of Allergy, Asthma, and Immunology, The Scripps Clinic and the Scripps Research Institute, La Jolla, CA.

出版信息

Allergy Asthma Clin Immunol. 2006 Sep 15;2(3):109-16. doi: 10.1186/1710-1492-2-3-109.

Abstract

With the judicious use of inhaled corticosteroids, beta2 agonists, and leukotriene modifiers, most patients with asthma are easily controlled and managed. However, approximately 5% of asthmatics do not respond to standard therapy and are classified as "difficult to control." 1 Typically, these are patients who complain of symptoms interfering with daily living despite long-term treatment with inhaled corticosteroids in doses up to 2,000 mug daily. Many factors can contribute to poor response to conventional therapy, and especially for these patients, a systematic approach is needed to identify the underlying causes. First, the diagnosis of asthma and adherence to the medication regimen should be confirmed. Next, potential persisting exacerbating triggers need to be identified and addressed. Concomitant disorders should be discovered and treated. Lastly, the impact and implications of socioeconomic and psychological factors on disease control can be significant and should be acknowledged and discussed with the individual patient. Less conventional and novel strategies for treating corticosteroid-resistant asthma do exist. However, their use is based on small studies that do not meet evidence-based criteria; therefore, it is essential to sort through and address the above issues before reverting to other therapy.

摘要

通过合理使用吸入性皮质类固醇、β2 受体激动剂和白三烯调节剂,大多数哮喘患者可得到轻松控制和管理。然而,约有 5%的哮喘患者对标准治疗无反应,被归类为“难以控制”。1 这些患者通常抱怨即使长期使用吸入皮质类固醇治疗,剂量高达每日 2000 微克,仍有症状干扰日常生活。许多因素可能导致对常规治疗反应不佳,对于这些患者,需要采用系统的方法来确定潜在的原因。首先,应确认哮喘的诊断和药物治疗方案的依从性。其次,需要识别和处理潜在的持续恶化触发因素。应发现并治疗并存疾病。最后,应认识到社会经济和心理因素对疾病控制的影响和意义,并与个体患者进行讨论。确实存在治疗皮质类固醇抵抗性哮喘的非传统和新型策略。但是,它们的使用基于不符合循证标准的小型研究;因此,在转向其他治疗方法之前,必须梳理和解决上述问题。

相似文献

1
The Difficult-to-Control Asthmatic: A Systematic Approach.
Allergy Asthma Clin Immunol. 2006 Sep 15;2(3):109-16. doi: 10.1186/1710-1492-2-3-109.
2
Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Cochrane Database Syst Rev. 2005 Oct 19(4):CD005535. doi: 10.1002/14651858.CD005535.
4
Difficult asthma.
Proc Am Thorac Soc. 2006;3(1):116-23. doi: 10.1513/pats.200510-115JH.
5
Diagnosis and treatment of refractory asthma.
Eur Rev Med Pharmacol Sci. 2008 Sep-Oct;12(5):315-20.
8
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
Cochrane Database Syst Rev. 2005 Jan 25(1):CD003137. doi: 10.1002/14651858.CD003137.pub2.
9
Benefit-risk assessment of long-acting beta2-agonists in asthma.
Drug Saf. 2004;27(4):243-70. doi: 10.2165/00002018-200427040-00003.

引用本文的文献

本文引用的文献

1
Evidence of a role of tumor necrosis factor alpha in refractory asthma.
N Engl J Med. 2006 Feb 16;354(7):697-708. doi: 10.1056/NEJMoa050580.
3
Steroid-unresponsive asthma.
Semin Respir Crit Care Med. 2002 Aug;23(4):387-98. doi: 10.1055/s-2002-34353.
5
Can subjective asthma symptoms be learned?
Psychosom Med. 2005 May-Jun;67(3):454-61. doi: 10.1097/01.psy.0000160470.43167.e2.
7
Intramuscular triamcinolone for difficult asthma.
Pediatr Pulmonol. 2005 May;39(5):421-5. doi: 10.1002/ppul.20176.
8
Airway wall remodelling: the influence of corticosteroids.
Curr Opin Allergy Clin Immunol. 2005 Feb;5(1):43-8. doi: 10.1097/00130832-200502000-00009.
9
Outpatient treatment of chronic obstructive pulmonary disease: comparisons with asthma.
J Allergy Clin Immunol. 2004 Oct;114(4):715-24; quiz 725. doi: 10.1016/j.jaci.2004.07.044.
10
"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids.
Am J Respir Crit Care Med. 2004 Sep 15;170(6):601-5. doi: 10.1164/rccm.200404-440OC. Epub 2004 Jun 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验